The Effect of Weight Loss on Serum Mannose-Binding Lectin(MBL) Levels

The Effect of Weight Loss on Serum Mannose-Binding Lectin (MBL) Levels

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00854412

Acronym

WLMBL

Enrollment

Registered

2009-03-03

Start date

1995-03-31

Completion date

1995-06-30

Last updated

2009-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Weight Loss

Keywords

Obesity, Weight loss, Very low-calorie diet, Mannose-binding lectin, Insulin resistance

Brief summary

High levels of mannose-binding lectin (MBL), an activator of a part of the immune system called the complement system, have been associated with increased mortality and risk of early signs of kidney damage in patients with type 2 diabetes. The effect of weight loss and changes in insulin resistance on MBL levels have been poorly elucidated. This study includes 36 nondiabetic obese subjects, who will receive a very low- calorie diet (VLCD) of 800 kcal/day for 8 weeks. Fasting blood samples will be obtained at baseline and after 8 weeks of VLCD and concentrations of MBL, glucose and insulin will be measured. Insulin resistance is assessed using the HOMA-IR method.

Interventions

OTHERWeight loss

Very low-calorie diet (VLCD) of 800 kcal/day for 8 weeks

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Obese

Exclusion criteria

* Diabetes * Other severe disease

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026